Full Text View
Tabular View
No Study Results Posted
Related Studies
Genetics of Rheumatoid Arthritis
This study is ongoing, but not recruiting participants.
Study NCT00001678   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: July 23, 2009   History of Changes

November 3, 1999
July 23, 2009
July 1998
 
 
To establish the maximally tolerated dose of ZD6474 in patients with recurrent high-grade gliomas taking EIAED.
Complete list of historical versions of study NCT00001678 on ClinicalTrials.gov Archive Site
 
To obtain preliminary information regarding the spectrum of toxicities, and to obtain pharmacokinetic data on ZD6474 administered to patients with recurrent high-grade gliomas taking EIAED.
 
Genetics of Rheumatoid Arthritis
Genetics of Rheumatoid Arthritis: The North American Rheumatoid Arthritis Consortium

This study attempts to identify the genes responsible for rheumatoid arthritis (RA), or inflammation of the joints. It is known that genes play an important role in RA, but their number and significance have not been determined. RA tends to run in families. This study will examine the DNA (hereditary material) of patients with RA and their family members to try to determine which chromosomes(s) contain the genes responsible for the disease.

Patients with rheumatoid arthritis and their family members may be eligible for this study.

Participants with RA who have a brother or sister with RA will undergo the following procedures:

  • Review of their medical records
  • Medical history
  • Examination of the joints
  • Hand X-rays
  • Blood tests

Participants who 1) do not have RA but who have a relative with the disease, or 2) have RA and a relative other than a brother or sister who has the disease will provide a blood sample or a buccal (cheek) cell sample. Cheek cells are obtained by swishing a small amount of mouthwash in the mouth or by lightly bushing the inside of the cheek with a swab or brush.

The samples will be tested for rheumatoid factor, DNA studies, and HLA type (a blood type found on white blood cells). Certain HLA types have been associated with an increased risk or severity of RA.

The purpose of this protocol is to identify genetic susceptibility loci for rheumatoid arthritis. The Genetics and Genomics Branch of the Intramural Research Program of NIAMS has joined with several extramural centers to form the North American Rheumatoid Arthritis Consortium (NARAC). The Consortium intends to identify and obtain clinical specimens on a total of 1000 sibling pairs with rheumatoid arthritis; up to 100 sibling pairs will be recruited at the Clinical Center. Samples from parents and other family members will also be obtained, where appropriate.

Rheumatoid factors, HLA-DR typings, and hand films will be obtained on all sibling pairs. In addition, DNA will be extracted from peripheral blood or buccal scrapings. The DNA from all 1000 sibling pairs will be typed for a set of approximately 350 genetic markers in order to identify chromosomal regions likely to harbor genes conferring susceptibility to rheumatoid arthritis. For those chromosomal regions that are positive in this initial screen, families will be genotyped for additional markers to define disease-associated haplotypes, and high density single nucleotide polymorphism (SNP) analysis will be conducted to narrow the regions of interest. Candidate genes will be chosen from the narrowed regions of interest, and/or based on functional considerations, and will be screened for mutations in rheumatoid arthritis.

 
Observational
 
Rheumatoid Arthritis
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
99999999
 
 
  • INCLUSION CRITERIA:

SIBLING PAIR:

A diagnosis of rheumatoid arthritis in both sibs by the 1987 ACR criteria.

Definite bony erosions in at least one affected sibling.

Age of disease onset greater than 18 years and less than 60 years in at least one sibling.

Neither sibling has psoriasis, inflammatory bowel disease, or systemic lupus erythematosus.

BLOOD RELATIVES OF AFFECTED SIBLING PAIRS:

Age greater than 18 years.

Where possible, all other affected siblings will be invited to participate.

Where possible, both parents of affected siblings will be invited to participate.

Other relatives, both affected and unaffected, may be invited to participate if, in the opinion of the investigators, samples from these individuals would contribute important genetic information. Two cases in which this might happen are: a) extended families in which there are several affected individuals, where conventional linkage analysis might be applied; b) affected sibling pairs for which parents are unavailable, where additional siblings will provide information on parental alleles not transmitted to the affected siblings.

EXCLUSION CRITERIA FOR AFFECTED SIBLINGS:

Psoriasis, inflammatory bowel disease, systemic lupus erythematosus.

Inability to provide infomed consent.

The sole criterion for exclusion of adult blood relatives of affected sibling pairs would be inability to provide informed consent.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001678
 
980124, 98-AR-0124
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
 
 
National Institutes of Health Clinical Center (CC)
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP